07 Dec Sixera initiates its first clinical trial on SXR1096 in Netherton Syndrome

with the potential to be the first available treatment of the rare and serious skin disease Netherton syndrome Stockholm, December 7, 2021. The Swedish biotech company, Sixera Pharma (”Sixera”) has reached...